1. Cost-effective analyses in Breast Cancer Research and Treatment

   • Marc E. Lippman
   • Stephen Ethier
   • Daniel F. Hayes

   EditorialNotes 18 May 2009 Pages: 221 - 222

2. Terpenoids and breast cancer chemoprevention

   • Thangaiyan Rabi
   • Anupam Bishayee

   Review 19 July 2008 Pages: 223 - 239

   

3. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers

   • Jan P. A. Baak
   • Einar Gudlaugsson
   • Axel zur Hausen

   Review 30 July 2008 Pages: 241 - 254

   

4. Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review

   • Jennifer Flemming
   • Yolanda Madarnas
   • Jacob A. Franek

   Review 06 August 2008 Pages: 255 - 268

   

5. Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model

   • Jiangbing Zhou
   • Hao Zhang
   • Ying Zhang

   Preclinical Study 28 May 2008 Pages: 269 - 277

   

6. Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones

   • Shirley M. Potter
   • Roisin M. Dwyer
   • Michael J. Kerin

   Preclinical Study 04 June 2008 Pages: 279 - 287

   

7. The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance

   • Matthew J. Sikora
   • Kevin E. Cordero
   • James M. Rae

   Preclinical Study 04 June 2008 Pages: 289 - 296

   

8. Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells

   • Marilena Lanzino
   • Cecilia Garofalo
   • Diego Sisci

   Preclinical Study 04 June 2008 Pages: 297 - 306

   

9. No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers

   • Amanda B. Spurdle
   • Andrew J. Deans
   • Georgia Chenevix-Trench

   Preclinical Study 10 June 2008 Pages: 307 - 313

10. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families

    • Thomas v. O. Hansen
    • Lars Jønson
    • Finn C. Nielsen

    Preclinical Study 12 June 2008 Pages: 315 - 323

    

11. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients

    • Wen-Jin Yin
    • Jin-Song Lu
    • Zhi-Ming Shao

    Preclinical Study 18 June 2008 Pages: 325 - 333

    

12. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer

    • Hye-Suk Han
    • Jungsil Ro
    • Seok Won Kim

    Clinical Trial 28 May 2008 Pages: 335 - 342

    

13. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy

    • Qifeng Yang
    • Meena S. Moran
    • Bruce G. Haffty

    Clinical Trial 31 May 2008 Pages: 343 - 348

    

14. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors

    • Olivier Brouckaert
    • Saskia Pintens
    • Patrick Neven

    Clinical Trial 16 July 2008 Pages: 349 - 358

    

15. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

    • T. Byrski
    • T. Huzarski
    • S. A. Narod

    Clinical Trial Open access 23 July 2008 Pages: 359 - 363

16. Psychological impact of recall in high-risk breast MRI screening

    • Suzanne M. O’Neill
    • Wendy S. Rubinstein
    • Robert R. Edelman

    Clinical Trial 26 July 2008 Pages: 365 - 371

17. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer

    • Rupert Bartsch
    • Brigitte Mlineritsch
    • on behalf of the Austrian Fulvestrant Registry

    Clinical Trial 26 July 2008 Pages: 373 - 380

    

18. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?

    • Catharina E. Jacobi
    • Geertruida H. de Bock
    • Christi J. van Asperen

    Epidemiology 30 May 2008 Pages: 381 - 390

    

19. CYP2C19*17 is associated with decreased breast cancer risk

    • Christina Justenhoven
    • Ute Hamann
    • Hiltrud Brauch

    Epidemiology 03 June 2008 Pages: 391 - 396

20. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer

    • Xinran Xu
    • Marilie D. Gammon
    • Jia Chen

    Epidemiology 03 June 2008 Pages: 397 - 404

    

21. High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations

    • Inmaculada de Juan
    • Eva Esteban
    • Pascual Bolufer

    Epidemiology 05 June 2008 Pages: 405 - 414

    

22. A retrospective study of quality of life in a community sample of patients with early stage breast cancer

    • Mark S. Walker
    • Lee S. Schwartzberg
    • Barry V. Fortner

    Epidemiology 17 April 2009 Pages: 415 - 422

    

23. Pattern of metastatic spread in triple-negative breast cancer

    • Rebecca Dent
    • Wedad M. Hanna
    • Steven A. Narod

    Epidemiology 10 June 2008 Pages: 423 - 428

    

24. The rising incidence of male breast cancer

    • Valerie Speirs
    • Abeer M. Shaaban

    Letter to the Editor 14 May 2008 Pages: 429 - 430

    

25. Dihydrofolate reductase (DHRF) 19-bp intron-1 deletion and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in breast cancer

    • Ragip Çam
    • Aydan Eroglu
    • Nejat Akar

    Letter to the Editor 24 May 2008 Pages: 431 - 432

26. The sensitivity of BRCA1 mutation carriers to ionising radiation: questions of methodology

    • Magdalena Chechlinska
    • Radoslawa Nowak

    Letter to the Editor 27 May 2008 Pages: 433 - 433

27. Link between insulin and metabolic disorders in cancer: does leptin play a key role?

    • Noemi Malandrino
    • Lorenzo Leggio
    • Esmeralda Capristo

    Letter to the Editor 17 June 2008 Pages: 435 - 436